A pproximately 5% to 10% of all patients will have some problems obtaining final union of their fractures. 1, 2 The most advanced form of difficulty is a fracture nonunion, where the normal biologic healing process ceases to the extent that solid bony union will not occur without further treatment.
Metabolic and endocrine abnormalities in patients with nonunions
Mark R. Brinker a , Daniel P. O'Connor b , Yomna T. Monla c and Thomas P. Earthman d A pproximately 5% to 10% of all patients will have some problems obtaining final union of their fractures. 1, 2 The most advanced form of difficulty is a fracture nonunion, where the normal biologic healing process ceases to the extent that solid bony union will not occur without further treatment.
In some cases, the etiology of a nonunion is clear, such as the patient with inadequate stabilization or a large gap between bony fragments. In other cases, however, a patient may present with a well-stabilized fracture that fails to unite in a seemingly healthy patient with good local biology at the site of injury.
Fracture nonunion is a multifactorial phenomenon. Predisposing mechanical, anatomical, and biological factors for nonunion include instability, inadequate vascularity, and poor bone-to-bone contact. A variety of other contributing factors, such as cigarette smoking and malnutrition, have also been described. 3 Abnormalities of vitamin D, calcium, and parathyroid hormone in particular may adversely affect fracture healing due to their importance in bone metabolism. [4] [5] [6] [7] [8] To the best of our knowledge, no prior large consecutive series has actually documented a relationship between metabolic and endocrine abnormalities and fracture nonunion.
In January 1998, we began to refer a subset of our patients with fracture nonunion who met certain screening criteria for a thorough endocrinology workup. The purpose of this study was to determine the effectiveness of our screening criteria for identifying metabolic and endocrine abnormalities in patients who present with a fracture nonunion. Our hypothesis was that a high proportion of patients who met
R E V I E W A R T I C L E A B S T R A C T

Objectives
To determine whether patients with unexplained nonunions, patients with a history of multiple low-energy fractures with at least one progressing to a nonunion, and patients with a nonunion of a nondisplaced pubic rami or sacral ala fracture would have an underlying metabolic or endocrine abnormality that had not been previously diagnosed.
Design
Case series.
Setting Tertiary referral center.
Patients and Intervention
From a larger series of 683 consecutive patients with nonunion seen by us between January 1998 and December 2005, 37 patients were referred to 1 of 2 clinically practicing endocrinologists to undergo an evaluation for metabolic and endocrine abnormalities. The screening criteria were: 1) an unexplained nonunion that occurred despite adequate reduction and stabilization (and debridement in initially infected cases) without obvious technical error and without any other obvious etiology; 2) a history of multiple low-energy fractures with at least one progressing to a nonunion; or 3) a nonunion of a nondisplaced pubic rami or sacral ala fracture.
Results
In all, 31 of the 37 patients (83.8%, 95% CI: 71.3% to 93.8%) who met our screening criteria had one or more new diagnoses of metabolic or endocrine abnormalities. The most common newly diagnosed abnormality was vitamin D deficiency (25 of 37 patients; 68%). Other newly diagnosed abnormalities included calcium imbalances, central hypogonadism, thyroid disorders, and parathyroid hormone disorders. All newly diagnosed abnormalities were treated medically. Eight patients who underwent no operative intervention following the diagnosis and treatment of a new metabolic or endocrine abnormality achieved bony union in an average of 7.6 months (range, 3 to 12 months) following their first visit to the endocrinologist.
Conclusions
Although our study does not prove a causal link between metabolic and endocrine abnormalities and either the development or healing of nonunions, 84% of the patients who met our screening criteria were found to have metabolic or endocrine abnormalities, and eight of our patients achieved bony union following medical treatment alone. All patients with nonunion who meet our screening criteria should be referred to an endocrinologist for evaluation because they are likely to have undiagnosed metabolic or endocrine abnormalities that may be interfering with bone healing.
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PATIENTS AND METHODS
Subjects
The study group was identified from a larger group of 683 consecutive patients with nonunion seen at our center by the first author between January 1998 and December 2005.
The diagnosis of nonunion was confirmed in all cases by the presence of one or more of the following: 1) gross motion at the injury site on physical examination; 2) obvious motion at the injury site under fluoroscopic stress views; 3) bridging bone on 0 of 4 cortices of the anteroposterior and lateral radiographs, as described by Heckman et al.; 9 4) a computed tomography (CT) scan showing no purposeful cross-sectional area of healing.
Of these 683 patients with nonunions, we referred 37 patients to 1 of 2 clinically practicing endocrinologists to undergo evaluation for metabolic and endocrine abnormalities (Table 1) . These endocrinologists were involved in the planning and execution of this study. The study protocol was approved by the facility's institutional review board.
The specific criteria for referral to an endocrinologist are outlined in Figure 1 and included any one of the following: 1) an unexplained nonunion that occurred despite adequate reduction and stabilization (and debridement in initially infected cases) without obvious technical error [10] [11] [12] [13] and without any other obvious etiology (26 patients); 2) a history of multiple low-energy fractures with at least one progressing to a nonunion (8 patients); or 3) a nonunion of a nondisplaced pubic rami or sacral ala fracture (3 patients). The determination as to whether each patient met the criteria for referral was evaluated by the orthopaedic surgeon during the initial history and physical examination. None of the other 646 patients with nonunions met the criteria and were therefore not referred to an endocrinologist.
The study group consisted of 27 women with an average age at presentation of 52.2 years and 10 men with an average age at presentation of 45.7 years ( Table 2 ). The average time between the initial fracture and presentation to our center was 22.1 months (range, 3 months to 104 months). The patients had undergone an average of 2.4 (range, 0 to 9) surgeries prior to referral to our center. The 37 patients had a total of 46 noncontiguous nonunion sites in 36 bones and 4 joints. The 46 nonunion sites were: femur (16), tibia (13), humerus (4), ankle (4), pubic rami (4), sacral ala (3), radius (1), ulna (1) ( Table 2) .
The distribution of nonunion types 3 at the 46 sites were: oligotrophic (23), atrophic (12) , infected (7) , and hypertrophic (4). Nonunion type was determined by the treating orthopaedic surgeon based on plain radiographs and computed tomography. 3 Oligotrophic nonunions were identified as those with an apparently adequate blood supply but little or no callus formation. 3 Atrophic nonunions were identified as those with an apparently inadequate blood supply and no callus formation. 3 Infected nonunions were identified as those with infection of bone or soft tissues or both at the nonunion site. 3 Hypertrophic nonunions were identified as those with abundant callus but a clear radiolucent line at the fracture site. 3 At the time of referral to the endocrinologist, none of the seven patients with seven sites that had been previously classified as an infected nonunion had any clinical signs or symptoms of active infection or any laboratory or radiographic studies that were diagnostic of ongoing infection.
Evaluation and Treatment
Evaluation for metabolic and endocrine abnormalities in the study group included blood and urine tests to identify hormonal, protein, mineral, and vitamin imbalances ( Table 1 ). All of the tests were ordered, evaluated, and interpreted by one of the two clinically practicing endocrinologists who were involved in this study.
The consulting endocrinologist provided medical treatment of metabolic and endocrine abnormalities ( Table 2 ). The treating orthopaedic surgeon provided treatment for the nonunion site; 27 of the patients underwent one or more surgical procedures, and 10 patients were treated nonoperatively.
Data Analysis
We computed the proportion and 95% confidence interval (95% CI) of patients with newly diagnosed metabolic or endocrine abnormalities as a result of this study. Analysis of variance was used to evaluate whether patient age differed between patients with metabolic and endocrine abnormalities and patients without these abnormalities. Chi-square tests were used to evaluate whether gender or nonunion type was related to the prevalence of metabolic and endocrine abnormalities. A P value of 0.05 or less was considered to be statistically significant.
RESULTS
In all, 31 of 37 patients (83.8%) who met our screening criteria and therefore underwent evaluation by an endocrinologist had one or more new diagnoses related to metabolic or endocrine abnormalities ( Table 2 ). Six of the 37 patients who met our screening criteria had no new metabolic or endocrine abnormality. The 95% confidence interval for having a metabolic or endocrine abnormality for patients with nonunion who met our screening criteria was 71.3% to 93.8%. Of the 31 patients, 24 had more than one metabolic or endocrine abnormality ( Table 2) .
With the numbers available, average age at presentation was not significantly different between patients with (49.9 years, SD ¼ 15.1 years) and without (53.8 years, SD ¼ 10.3 years) metabolic or endocrine abnormalities (P ¼ 0.531). With the numbers available, the prevalence of metabolic and endocrine abnormalities in the men (100.0%) and women (77.8%) in our study was not significantly different (P ¼ 0.162). With the numbers available, the prevalence of metabolic and endocrine abnormalities did not differ significantly by nonunion type: 17 of 23 oligotrophic sites (73.9%), 10 of 12 atrophic sites (83.3%), 7 of 7 infected sites (100%), 4 of 4 hypertrophic sites (100%; P ¼ 0.373).
The most common newly diagnosed abnormality was vitamin D deficiency in 25 of the 37 patients (68%, 95% CI ¼ 53% to 82%). Twenty-one of the 37 patients (57%) had vitamin Six of the 25 patients with a vitamin D deficiency were diagnosed with mild vitamin D deficiency, defined as vitamin D 25(OH) levels between 20 ng/mL and 30 ng/mL or vitamin D 1,25(OH) 2 levels between 15 pg/mL and 25 pg/mL. Nineteen of the 25 patients were diagnosed with frank vitamin D deficiency, defined as vitamin D 25(OH) below 20 ng/ mL or vitamin D 1,25(OH) 2 levels below 15 pg/mL. Abnormal 24-hour urine calcium was the second most common finding, newly identified in 13 of 37 patients (35%, 95% CI ¼ 23% to 53%); 10 of these 13 patients also had vitamin D deficiency. Abnormally low 24-hour urine calcium was found in 7 of the 37 patients. Abnormally high 24-hour urine calcium was found in 6 other patients.
Nine of the 37 patients (24%, 95% CI ¼ 14% to 41%) had newly identified abnormalities related to the thyroid gland. Three patients had elevated thyroid stimulating hormone; one of these three also had decreased free T 3 (triiodothyro-nine). Three patients had decreased thyroid stimulating hormone; one of these patients also had decreased T 3 and another one of these patients also had decreased T 3 and elevated T 4 (thyroxine). In the remaining 3 of the 9 patients, 2 had decreased T 3 and 1 had elevated T 3 . Five of the 9 patients were newly diagnosed with hypothyroidism, and 2 were newly diagnosed with autoimmune thyroiditis from overtreatment of hypothyroidism (iatrogenic hyperthyroidism).
Eight of the 37 patients (22%, 95% CI ¼ 12% to 38%) had newly identified abnormalities of one or more hormones related to the reproductive system. Five of the 37 patients (4 men and 1 woman) had newly diagnosed central hypogonadism.
Abnormally high alkaline phosphatase was newly identified in 6 of the 37 patients (16%, 95% CI ¼ 8% to 32%). One of these 6 patients and 1 additional patient had newly identified high serum phosphate levels.
Other newly identified abnormalities were less common. Four of the 37 patients (11%, 95% CI ¼ 5% to 26%) had elevated parathyroid hormone levels. Two of the 37 patients had hyperprolactemia (5%, 95% CI ¼ 2% to 18%). One of the 37 patients had increased growth hormone (3%, 95% CI ¼ 1% to 14%).
Thirty of the 31 patients with newly identified metabolic or endocrine abnormalities after referral to us achieved bony union in an average of 9.6 months (range, 2 to 23 months) after the endocrinology evaluation and medical treatment. One patient (patient 20) with a subtrochanteric nonunion who was newly diagnosed with vitamin D deficiency and iatrogenic hyperthyroidism underwent total hip arthroplasty because there was inadequate bone stock for revision open reduction internal fixation. Ultimately, 27 of the 31 patients with newly identified metabolic or endocrine abnormalities underwent operative treatment by us ( in an average of 7.6 months (range, 3 to 12 months) following their first visit to the endocrinologist. Four of these 8 patients received no surgery from us; the other four patients received surgery from us before being referred for their endocrinology examination. Five of the 6 patients with no newly identified metabolic or endocrine abnormalities achieved bony union, 4 following operative intervention and 1 following nonoperative treatment. The sixth patient underwent a total hip arthroplasty to treat a femoral neck nonunion of 12 months duration.
DISCUSSION
Our sample data indicates that nearly 85% of patients with nonunion who met our screening criteria had previously undiagnosed metabolic or endocrine abnormalities. This finding did not vary by patient age, gender, or nonunion type. Our results suggest that metabolic or endocrine abnormalities play a role in the development or persistence of nonunion in some patients. We recommend that a patient who has a nonunion and meets our criteria be referred for a complete metabolic and endocrine evaluation. While our study does not prove a causal link between metabolic and endocrine abnormalities and either the development or healing of nonunions, most of the patients who met our criteria were found to have metabolic or endocrine abnormalities. Furthermore, eight of our patients achieved bony union following medical treatment alone after the identification of a new metabolic or endocrine abnormality.
The response to fracture involves many metabolic and endocrine factors, including biochemical interactions of growth factors, bone morphogenetic proteins, vitamins, minerals, and hormones. Impairment of any of these factors could potentially affect fracture healing. Many endocrine and metabolic disorders that affect these factors have been shown to be associated with alterations in bony metabolism. [4] [5] [6] [14] [15] [16] [17] [18] [19] Several authors have described adverse effects on bone healing and bone structure among patients with various endocrine and metabolic abnormalities. Diamond and coauthors reported that the prevalence of vitamin D deficiency (,20 ng/mL) and hypogonadism (serum free testosterone,11 pg/mL) among 41 men over 60 years of age who had sustained osteoporotic hip fractures was higher than the prevalence of these abnormalities among age-matched controls. 20 Lancourt and Hochberg reported four patients for whom hyperparathyroidism was identified as a causative factor for fracture nonunion. 21 Misol and colleagues reported a case in which a patient with low growth hormone levels had delayed healing (20 weeks without callus formation) of a femoral shaft fracture and hypothesized that the hormonal deficiency may have had a role in the delay of bony union. 22 In a case-control study of 107 patients, Rosen and colleagues reported that patients with growth hormone deficiency have a three times greater risk of fracture, suggesting that growth hormone contributes to bone strength. 23 Several other factors affect the endocrine system and various metabolic pathways related to bone formation, such as diabetes mellitus, 15-17 malnutrition, 18, 19 cigarette smoking, [28] [29] [30] [31] [32] [33] [34] alcohol abuse, 35, 36 and certain medications (eg, nonsteroidal antiinflammatory drugs). [37] [38] [39] [40] [41] Vitamin D deficiency may account for the concomitant findings of elevated alkaline phosphatase, elevated parathyroid hormone, and decreased calcium observed in some of our patients. 5, 6 All of these factors have been shown to be associated with impaired fracture healing. 14 Long-term exposure to chronically elevated parathyroid hormone levels increases bone resorption, as observed in secondary hyperparathyroidism in chronic renal disease. 4 Intestinal calcium absorption is less effective with vitamin D deficiency, thus depriving the fracture site of the calcium necessary for mineralization. Any of these correlates of vitamin D deficiency can adversely affect fracture healing and conceivably contribute to the development of nonunion.
An elevated alkaline phosphatase level, an indicator of bone formation, is a normal reaction within 3 to 6 weeks of fracture. [24] [25] [26] [27] In our patients with nonunion, the presence of elevated alkaline phosphatase well beyond six weeks may represent a failing attempt to heal the fracture site. The failure to heal despite apparent active bone formation in these cases may be attributable to vitamin D deficiency causing inadequate calcium availability or increased bone resorption dueto chronically elevated parathyroid hormone levels or both.
Based on the results of our investigation, we make several recommendations. First, all patients with nonunion who meet our screening criteria as outlined in Figure 1 should be referred to an endocrinologist for evaluation. According to our data, patients with a nonunion who meet our criteria are likely to have undiagnosed metabolic or endocrine abnormalities. The goal of the evaluation is to identify any metabolic or endocrine abnormalities and to have the endocrinologist institute medical treatment. Treatment of the metabolic or endocrine abnormalities may facilitate the biological component of bone healing during orthopaedic treatment of the nonunion.
Second, we encourage further investigation to determine whether all patients with nonunion should receive an endocrinology evaluation. The biological factors that contribute to development of a nonunion are currently not completely understood. Patients with clinically undetected metabolic or endocrine abnormalities may be at greater risk for persistent nonunion, just as patients with certain metabolic disorders are known to be at greater risk for fracture. 23, [42] [43] [44] Third, it may be possible to develop simple clinical screening criteria for patients with fractures to identify those who are at risk for developing nonunion due to an undiagnosed metabolic or endocrine abnormality. If metabolic or endocrine abnormalities are shown to be a causative factor in the development of nonunion, identifying patients with such abnormalities and providing the appropriate medical treatment early in the fracture healing process may decrease the incidence of fracture nonunion. For example, given the high prevalence of inadequate vitamin D levels in the general population, 45 it is likely that many patients who sustain a fracture may also have a vitamin D deficiency that can contribute to the formation of nonunion. Development of such screening criteria would require prospective studies of large series or samples of patients with a fracture who all receive an endocrinology evaluation. Criteria for referral as outlined in Figure 1 : A, an unexplained nonunion that occurred despiteadequat i adequate reduction anc I stabilization (and debridement in initially infected cases) without obvious technical error [16] [17] [18] [19] and without any other obvious etiology; B, a history of multiple low-energy fractures with at least one progressing to a nonunion; C, a nonunion of a nondisplaced pubic rami or sacral fracture. It was beyond the intent and scope of this study to show that metabolic and endocrine abnormalities caused nonunion in our patients. While we believe our data is compelling, with a prevalence of 84% of newly diagnosed metabolic and endocrine abnormalities in patients with nonunion who met our screening criteria, our study design did not allow us to prove a causal link. It was also beyond the intent and scope of our investigation to demonstrate the effectiveness of medical treatment on healing the nonunion in our patients, although in eight cases (such as patient 31, Figure 2 ) orthopaedic treatment had failed and the medical intervention alone led to solid bony union.
In conclusion, our screening criteria can be used to identify patients with a nonunion who are likely to have undiagnosed metabolic or endocrine abnormalities that may be interfering with the bone healing process. All patients with nonunion who meet our screening criteria should be referred to an endocrinologist for evaluation. Future studies are needed to confirm the causal association of metabolic and endocrine abnormalities with the development of nonunion and to develop appropriate clinical screening criteria to identify patients with fractures who are at high risk for nonunion due to these abnormalities. A, Anteroposterior and lateral radiograph of a 37-year-old man (patient 31), who was referred 24 months following intramedullary nail fixation of a humeral shaft fracture. The patient had no significant past medical history and the workup for infection, including aspiration of the nonunion site and blood work, was negative. The patient was taken to the operating room and underwent nail removal, trimming of the nonunion site, autogenous posterior iliac crest bone grafting, and plate stabilization with compression applied across the nonunion site. B, Anteroposterior and lateral radiographs 2 weeks following nonunion treatment as described above. C, Anteroposterior radiograph and CT scan 6 months later shows a persistent nonunion with no cross-sectional area of healing. At this point the patient continued to complain of pain and was referred for endocrinology evaluation. The evaluation revealed vitamin D deficiency [the patient had high intact parathyroid hormone (83 pg/mL) and low 25-hydroxyvitamin D (14 ng/mL)]. The patient was started on calcium 500 mg with vitamin D 800 IU three times per day to treat his vitamin D deficiency. D, Anteroposterior and lateral radiographs 5 months following initiation of medical treatment show solid bony union; no further operative intervention was performed. The patient has returned to full painless function at preinjury levels.
